{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:44:45Z","timestamp":1793130285132,"version":"4.5.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The purpose of this study is to describe the current clinical situation of patients with painful diabetic peripheral neuropathy (DPN) and related anxiety, depression, and the quality of life of patients in mainland China, and to report the current status of the use of analgesics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Between June 15, 2021, and October 15, 2021, a total of 401 participants participated in the study. Recruitment was carried out using a multi-level sampling method. Participants\u2019 demographics, medical history, analgesic use, Michigan Symptom Score (MNSI), Numerical Rating Scale (NRS) pain score, Patient Health Questionnaire 9 (PHQ-9) score, Generalized Anxiety Disorder 7 (GAD) -7) Score, quality of life score (SF-12) and diabetes treatment status were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the participants, there were 236 male patients and female patients. Participants were 322 patients over 40 years old. Regarding the use of analgesics: 132 patients reported using analgesics, 221 patients reported not using analgesics, and 48 patients reported having used analgesics. The results of the scale showed that the scores of NRS, GAD-7, PHQ-9 and SF-12 were 5.12 \u00b1 2.15, 6.33 \u00b1 3.67, 8.46 \u00b1 4.07 and 47.84 \u00b1 19.92 for patients who used analgesics, Compared with patients who did not use analgesics (NRS: 1.99 \u00b1 1.7, GAD-7: 1.81 \u00b1 2.81, PHQ-9: 3.13 \u00b1 4.10, SF-12: 78.34 \u00b1 21.66) there are significant differences (p&amp;lt; 0.001). In addition, patients\u2019 NRS scores are also closely related to GAD-7, PHQ-9 and SF-12 scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The severity of symptoms, mental status and quality of life of patients who used analgesics were more severe than those of patients who did not use analgesics. Pregabalin is still the preferred analgesic for patients with painful DPN, and the use of opioids in my country is extremely low, which is consistent with current international guidelines. Age, diabetic duration, DPN duration, PHQ-9 score, GAD-7 score and SF-12 scores are closely related to NRS pain scores. In addition, there are still a considerable number of patients who have not used analgesics due to financial burdens and other reasons, suggesting that China still has insufficient pain management in DPN patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.813210","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T05:15:16Z","timestamp":1642742116000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Status of Analgesic Drugs and Quality of Life Results for Diabetic Peripheral Neuropathy in China"],"prefix":"10.3389","volume":"12","author":[{"given":"Jingxuan","family":"Lian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399812666160624122605","article-title":"Diabetic Neuropathy: Update on Pathophysiological Mechanism and the Possible Involvement of Glutamate Pathways","volume":"13","author":"Hussain","year":"2017","journal-title":"Curr Diabetes Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0092-1","article-title":"Diabetic Neuropathy","volume":"5","author":"Feldman","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.nurpra.2016.08.034","article-title":"Diabetic Peripheral Neuropathy: Evaluation and Management","volume":"13","author":"Hershey","year":"2016","journal-title":"J\u00a0Nurse Practitioners"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-014-0541-x","article-title":"Microvascular Dysfunction in the Context of Diabetic Neuropathy","volume":"14","author":"Stirban","year":"2014","journal-title":"Curr Diabetes Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201810_16058","article-title":"Microangiopathy in Diabetic Polyneuropathy Revisited","volume":"22","author":"Fang","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e000752","DOI":"10.1136\/bmjdrc-2019-000752","article-title":"Deficits in Systemic Biomarkers of Neuroinflammation and Growth Factors Promoting Nerve Regeneration in Patients With Type 2 Diabetes and Polyneuropathy","volume":"7","author":"Ziegler","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neurol.2018.08.005","article-title":"Pharmacological Treatments of Neuropathic Pain: The Latest Recommendations","volume":"175","author":"Attal","year":"2019","journal-title":"Rev Neurol (Paris)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/antiox9100950","article-title":"Key Developments in the Potential of Curcumin for the Treatment of Peripheral Neuropathies","volume":"9","author":"Caillaud","year":"2020","journal-title":"Antioxid (Basel)"},{"key":"B9","article-title":"Diabetic Neuropathy and Painful Diabetic Neuropathy: Cinderella Complications in South East Asia","volume":"68","author":"Almuhannadi","year":"2018","journal-title":"J\u00a0Pak Med Assoc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1515\/sjpain-2018-0094","article-title":"Cause-Specific Mortality of Patients With Severe Chronic Pain Referred to a Multidisciplinary Pain Clinic: A Cohort Register-Linkage Study","volume":"19","author":"Vaegter","year":"2019","journal-title":"Scand J Pain"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e025722","DOI":"10.1136\/bmjopen-2018-025722","article-title":"Painful Diabetic Peripheral Neuropathy Study of Chinese OutPatiEnts (PDN-SCOPE): Protocol for a Multicentre Cross-Sectional Registry Study of Clinical Characteristics and Treatment in China","volume":"9","author":"Zhang","year":"2019","journal-title":"BMJ Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.17.11.1281","article-title":"A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy","volume":"17","author":"Feldman","year":"1994","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global Estimates of the Prevalence of Diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results From the International Diabetes Federation Diabetes Atlas, 9(Th) Edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"B15","article-title":"Risk Factors and Pain Status Due to Diabetic Neuropathy in Chronic Long-Term Diabetic Patients in a Chinese Urban Population","volume":"125","author":"Ji","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DMSO.S37415","article-title":"Burden of Illness Associated With Painful Diabetic Peripheral Neuropathy Among Adults Seeking Treatment in the US: Results From a Retrospective Chart Review and Cross-Sectional Survey","volume":"6","author":"Sadosky","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.01.018","article-title":"Neuropathic Pain: Principles of Diagnosis and Treatment","volume":"90","author":"Gilron","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0241387","DOI":"10.1371\/journal.pone.0241387","article-title":"Diabetic Polyneuropathy With\/Out Neuropathic Pain in Mali: A Cross-Sectional Study in Two Reference Diabetes Treatment Centers in Bamako (Mali), Western Africa","volume":"15","author":"Maiga","year":"2020","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.pmrj.2011.03.008","article-title":"Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation","volume":"3","author":"Bril","year":"2011","journal-title":"PM R"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS Guidelines on the Pharmacological Treatment of Neuropathic Pain: 2010 Revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur J Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/754693","article-title":"Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement From the Canadian Pain Society","volume":"19","author":"Moulin","year":"2014","journal-title":"Pain Res Manag"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.12.003","article-title":"Prevalence and Clinical Implications of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes: Results From a Nationwide Hospital-Based Study of Diabetic Neuropathy in Korea","volume":"103","author":"Kim","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e74195","DOI":"10.1371\/journal.pone.0074195","article-title":"Chronic Pain With Neuropathic Characteristics in Diabetic Patients: A French Cross-Sectional Study","volume":"8","author":"Bouhassira","year":"2013","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5214\/ans.0972-7531.1118409","article-title":"Painful Diabetic Neuropathy: An Update","volume":"18","author":"Kaur","year":"2011","journal-title":"Ann Neurosci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.813210\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T05:15:21Z","timestamp":1642742121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.813210\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":24,"alternative-id":["10.3389\/fendo.2021.813210"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.813210","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"article-number":"813210"}}